Two biotechs, SIGA and PharmAthene, vying to establish a foothold in the potentially vast biodefense market are in the midst of duking it out in a multibillion dollar legal battle. The crux of the dispute is a smallpox vaccine …
Paris-based pharma Sanofi-Aventis has pushed back its offer deadline for Massachusetts-based biotech Genzyme by six weeks. All other terms, including the $69 per share bid, remain unchanged. So far, very few shareholders have r…
As part of its efforts to expand into the biotech market, Johnson & Johnson is making a long-anticipated bid for Dutch vaccine maker Crucell — in spite of Crucell’s recent manufacturing troubles.
Continue read…
Much like Dendreon, which has a promising prostate cancer drug, ImmunoCellular is developing a cancer drug. In this case, it battles brain cancer, and a Phase I trial turned in remarkable results. But unlike Dendreon, ImmunoCel…
At a liver disease conference in Boston, one highlight is expected to be reports from Achillion about its new hepatitis C treatments, especially ACH-1625. The buzz is growing that the little biotech is attracting the attention …